Trader consensus heavily favors no new COVID-19 variant of concern before 2027 because SARS-CoV-2 continues evolving within established Omicron sublineages without meeting WHO criteria for elevated severity, transmissibility, or immune escape that would warrant reclassification. Dominant strains such as XFG and related JN.1 descendants account for the majority of sequences yet remain designated variants under monitoring with low additional public health risk per recent assessments. Updated vaccines targeting XFG for the 2026-2027 season reflect routine adaptation rather than crisis response, while surveillance shows stable hospitalization and mortality trends. Although highly divergent lineages like BA.3.2 continue under watch for potential immune evasion, they lack clear competitive advantage so far. Unexpected mutations could still shift dynamics before year-end 2026, but the current pattern of gradual change supports the market's implied probability.